Invokamet xr fda approval date?

Invokamet XR received FDA approval on [1] April 14, 2016. [1] This combination medication contains extended-release metformin and the SGLT2 inhibitor canagliflozin. [1]

What is Invokamet XR used for?

Invokamet XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when both canagliflozin and metformin are appropriate. [1] It is also prescribed when treatment with both canagliflozin and metformin is needed. [1]

When does Invokamet XR's patent expire?

The patent expiry for Invokamet XR involves multiple components. The patent for canagliflozin, a key ingredient, has an expected expiry around 2028, though this can vary due to factors like patent extensions and challenges. [2] Metformin, an older drug, is off-patent. Information on specific patents and their expiry dates for combination drugs like Invokamet XR can be complex and is often tracked by specialized services like DrugPatentWatch.com. [2]

Can generic versions of Invokamet XR be made?

Generic versions of Invokamet XR can potentially be developed and marketed once the relevant patents for canagliflozin expire and any periods of market exclusivity conclude. The development of generic combination drugs requires approval for each active ingredient in the specific dosage and formulation. [2]